RxDoctor Payments Data

Vanessa Sarquis, MD

Family Medicine · Riverview, FLNPI 1851700967

Payments from drug & device makers

$15,500in general payments, 2019–2025

Across 923 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Amarin Pharma, Inc.$882
  • plus $8K from 48 others

What the payments were for

  • Food & beverage$15,488100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,500 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$74,316
Medicare patients
147
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$129,610
FarxigaDapagliflozin Propanediol95$115,323
EliquisApixaban88$112,125
OzempicSemaglutide43$51,863
MounjaroTirzepatide31$42,369
EntrestoSacubitril/Valsartan31$33,600
XareltoRivaroxaban29$33,501
TrulicityDulaglutide14$19,983
GemtesaVibegron16$18,509
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,453
Atorvastatin Calcium926$7,539
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,389
Tresiba Flextouch U-100Insulin Degludec12$4,792
SymbicortBudesonide/Formoterol Fumarate14$4,322
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$584$138,063106 claims
AstraZenecaFarxiga, Symbicort$1,873$119,645109 claims
PfizerEliquis$1,126$112,12588 claims
Lilly USA, LLCMounjaro, Trulicity$1,090$62,35345 claims
Novo NordiskOzempic$1,179$51,86343 claims
NovartisEntresto$181$33,60031 claims
Johnson & JohnsonXarelto$412$33,50129 claims
Sumitomo Pharma America, Inc.Gemtesa$61$18,50916 claims
GSKShingrix$412$3,97118 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$151$3,74411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →